Metformin Aurovitas

Metformin, the active ingredient in Metformin Aurovitas, is a Biguanide presented as an oral tablet for oral use. It reduces hepatic glucose production and improves insulin sensitivity in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for the management of hyperglycemia in type 2 diabetes mellitus, acting on glucose metabolism.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels - Prediabetes: improves insulin sensitivity and may delay progression to diabetes - Polycystic ovary syndrome: reduces insulin resistance and helps restore ovulatory function

Metformin may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate upset stomach - Diarrhea: frequent loose stools, especially at treatment start - Abdominal discomfort: cramping or bloating - Metallic taste: transient alteration of taste perception - Loss of appetite: reduced desire to eat - Vomiting: occasional episodes

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis - Severe hypoglycemia: usually when combined with other glucose‑lowering agents - Hepatic dysfunction: elevated liver enzymes or hepatitis - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anemia: unexplained decrease in hemoglobin - Pancreatitis: inflammation of the pancreas

Before initiating Metformin Aurovitas, several safety considerations should be reviewed.

- Renal function: assess creatinine clearance and avoid use in severe renal impairment - Liver disease: use with caution in patients with hepatic dysfunction - Cardiac failure: monitor for signs of decompensation - Alcohol consumption: limit intake to reduce risk of lactic acidosis - Vitamin B12 monitoring: consider periodic testing for deficiency - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight

Metformin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of renal impairment and lactic acidosis - Cimetidine: may raise metformin plasma concentrations - Alcohol: potentiates risk of lactic acidosis

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms - Diuretics: affect renal clearance of metformin - ACE inhibitors or ARBs: require monitoring of renal function and electrolytes